Somewhat Favorable News Coverage Somewhat Unlikely to Impact CytomX Therapeutics (CTMX) Share Price
News stories about CytomX Therapeutics (NASDAQ:CTMX) have been trending somewhat positive recently, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CytomX Therapeutics earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.1733411739958 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of CytomX Therapeutics (NASDAQ:CTMX) opened at 15.74 on Friday. CytomX Therapeutics has a 12-month low of $9.85 and a 12-month high of $20.02. The company has a 50 day moving average price of $14.47 and a 200-day moving average price of $14.68. The firm’s market cap is $580.29 million.
CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by $0.30. CytomX Therapeutics had a negative net margin of 206.33% and a negative return on equity of 84.61%. The business had revenue of $8.75 million during the quarter, compared to analyst estimates of $4.95 million. Analysts expect that CytomX Therapeutics will post ($1.47) EPS for the current year.
Several equities analysts have issued reports on the company. BidaskClub cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Cann reiterated a “hold” rating on shares of CytomX Therapeutics in a research report on Tuesday, August 8th. Cowen and Company reiterated a “buy” rating on shares of CytomX Therapeutics in a research report on Wednesday, June 28th. Jefferies Group LLC reiterated a “buy” rating and set a $25.00 target price on shares of CytomX Therapeutics in a research report on Tuesday, June 6th. Finally, ValuEngine cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. CytomX Therapeutics currently has a consensus rating of “Hold” and an average price target of $25.60.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact CytomX Therapeutics (CTMX) Share Price” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/08/25/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-cytomx-therapeutics-ctmx-share-price.html.
In other CytomX Therapeutics news, CFO Debanjan Ray sold 2,500 shares of the stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $15.47, for a total value of $38,675.00. Following the sale, the chief financial officer now directly owns 22,126 shares in the company, valued at $342,289.22. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Frederick W. Gluck sold 5,000 shares of the stock in a transaction on Monday, June 26th. The stock was sold at an average price of $14.61, for a total transaction of $73,050.00. The disclosure for this sale can be found here. Insiders sold 39,343 shares of company stock worth $606,856 over the last 90 days. 4.70% of the stock is currently owned by company insiders.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Stock Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related stocks with our FREE daily email newsletter.